97 results about "Systemic blood" patented technology

A method is provided for facilitating a diagnosis of a condition of a subject, including applying a current to a site of the subject selected from the list consisting of: a sphenopalatine ganglion (SPG) of the subject, and a neural tract originating in or leading to the SPG, and configuring the current to increase conductance of molecules from brain tissue of the subject through a blood brain barrier (BBB) of the subject into a systemic blood circulation of the subject. The method also includes sensing a quantity of the molecules from a site outside of the brain of the subject, following initiation of application of the current.

Apparatus is provided for delivering a Non Steroidal Anti-Inflammatory Drug (NSAID) supplied to a body of a subject for delivery to at least a portion of a central nervous system (CNS) of the subject via a systemic blood circulation of the subject, including a stimulator adapted to stimulate at least one site of the subject, so as to cause an increase in passage of the NSAID from the systemic blood circulation across a blood brain barrier (BBB) of the subject to the portion of the CNS, during at least a portion of the time that the NSAID is present in the blood, the site selected from the list consisting of: a sphenopalatine ganglion (SPG) of the subject, an anterior ethmoidal nerve of the subject, a posterior ethmoidal nerve of the subject, a communicating branch between an anterior ethmoidal nerve and a retro-orbital branch of an SPG of the subject, a communicating branch between a posterior ethmoidal nerve and a retro-orbital branch of an SPG of the subject, a greater palatine nerve of the subject, a lesser palatine nerve of the subject, a sphenopalatine nerve of the subject, a communicating branch between a maxillary nerve and an SPG of the subject, a nasopalatine nerve of the subject, a posterior nasal nerve of the subject, an infraorbital nerve of the subject, an otic ganglion of the subject, an afferent fiber going into the otic ganglion of the subject, an efferent fiber going out of the otic ganglion of the subject, a vidian nerve of the subject, a greater superficial petrosal nerve of the subject, and a lesser deep petrosal nerve of the subject.

A catheter system is provided for accessing the coronary ostia transluminally from a peripheral arterial access site, such as the femoral artery, and for inducing cardioplegic arrest by direct infusion of cardioplegic solution into the coronary arteries. In a first embodiment, the catheter system is in the form of a single perfusion catheter with multiple distal branches for engaging the coronary ostia. In a second embodiment, multiple perfusion catheters are delivered to the coronary ostia through a single arterial cannula. In a third embodiment, multiple perfusion catheters are delivered to the coronary ostia through a single guiding catheter. In a fourth embodiment, multiple catheters are delivered to the coronary ostia through a single guiding catheter which has distal exit ports that are arranged to direct the perfusion catheters into the coronary ostia. In each embodiment, the catheters are equipped with an occlusion means at the distal end of the catheter for closing the coronary ostia and isolating the coronary arteries from the systemic blood flow. The occlusion means can take the form of an inflatable occlusion balloon cuff, a tapered occlusion device or an O-ring encircling the distal end of the catheter. An optional ventricular venting catheter can be included in the system for venting blood and fluids from the left ventricle of the heart. The catheter system is combined with a femoral-to-femoral cardiopulmonary bypass system to provide a system for cardioplegic arrest and total cardiopulmonary support during minimally invasive cardiac surgical procedures.

A method to treat solid tumors and other oncological diseases consists of parenterally injecting an agent which destroy's blood's extracellular DNA into the systemic blood circulation of a cancer patient to slow down malignant. The agent is embodied in the form of a DNAse enzyme and, more particularly, as a bovine pancreatic DNAse. Doses from 50,000-250,000,000 Kunz units / day are injected for 5-360 days. A binding agent or an agent that modifies the chemical composition of the blood extracellular DNA is additionally injected into the blood. This modifying agent is preferably an enzyme-ribonuclease.

A transdermal drug delivery system for treatment of ophthalmic diseases comprising a structure that a plaster layer containing a remedy for ophthalmic diseases is provided on a support, wherein the system is applied to a skin surface including a front surface of an eyelid to administer the remedy for ophthalmic diseases in the plaster layer to an ophthalmic topical tissue by percutaneous permeation substantially without being administered through a systemic blood flow. Use of the transdermal drug delivery system for treatment of ophthalmic diseases, comprising applying the transdermal drug delivery system to a skin surface including a front surface of an eyelid to transfer the remedy for ophthalmic diseases in the plaster layer to an ophthalmic topical tissue by percutaneous permeation substantially without being administered through a systemic blood flow, and a method for transferring the remedy for ophthalmic diseases to the ophthalmic topical tissue.

Disclosed are methods for providing sustained systemic blood concentrations of orally delivered drugs. Still further, disclosed are compounds and pharmaceutical compositions that are used in such methods.

This invention relates to proteins (e.g., peptides) that are capable of facilitating transport of an active agent through a human or animal gastro-intestinal tissue, and derivatives (e.g., fragments) and analogs thereof, and nucleotide sequences coding for said proteins and derivatives. The proteins of the invention have use in facilitating transport of active agents from the lumenal side of the GIT into the systemic blood system, and / or in targeting active agents to the GIT. Thus, for example, by binding (covalently or noncovalently) a protein of the invention to an orally administered drug, the drug can be targeted to specific receptor sites or transport pathways which are known to operate in the human gastrointestinal tract, thus facilitating its absorption into the systemic system.

The invention provides a full-automatic retinal blood vessel analysis method and system suitable for intelligent portable equipment. The invention improves a saliency feature method by adding a preprocessing step which comprises performing homogenization on a fundus image and removing the central light reflection treatment of the blood vessel, thereby realizing rapid segmentation of the retinal blood vessel. The method has the advantages of good stability, simple operation and high speed. The invention realizes accurate analysis of various retinal blood vessels and realizes the combination with intelligent portable equipment by optimizing algorithm complexity and operation speed, so computer-aided diagnosis can provide systemic blood vessel analysis with strong applicability, stable calculation and high precision in retinal image analysis.

The present invention relates to one kind of plant leavening prepared by using plant with hot and fragrant smell of propylene sulfide, yeast and lactobacillus and through fermentation. The present invention also relates to the preparation process of the leavening and its application is treating presbyopia, cataract and other diseases, promoting blood circulation; improving the functions of sexual organs, kidney, cardiac and cerebral vascular system, digestive system, etc.; resisting oxidation, senility and fatigue; lowering blood fat, blood sugar and blood pressure; etc.

A method to treat solid tumors and other oncological diseases consists of parenterally injecting an agent which destroy's blood's extracellular DNA into the systemic blood circulation of a cancer patient to slow down malignant. The agent is embodied in the form of a DNAse enzyme and, more particularly, as a bovine pancreatic DNAse. Doses from 50,000-250,000,000 Kunz units / day are injected for 5-360 days. A binding agent or an agent that modifies the chemical composition of the blood extracellular DNA is additionally injected into the blood. This modifying agent is preferably an enzyme-ribonuclease.

The vagina administrated mifepristone preparation for birth control and health reproduction consists of mifepristone or nanometer mifepristone liposome particle as main component, excipient, osmosis promoter, pH regulator, preservative, surfactant, solvent, water and other pharmaceutically acceptable components, and may be prepared into gel, film or other preparation forms. The vagina administrated mifepristone preparation is absorbed through vagina mucous membrane into blood circulation, and has high bioavailability, lowered dosage, less toxic side effect and less stimulation.

A method for modifying a property of a brain of a patient includes presenting an odorant to an air passage of the patient, the odorant having been selected for presentation to the air passage because it is such as to increase conductance of molecules from a systemic blood circulation of the patient through a blood brain barrier (BBB) of the brain into brain tissue of the patient. The molecules are selected from the group consisting of: a pharmacological agent, a therapeutic agent, an endogenous agent, and an agent for facilitating a diagnostic procedure.

This invention relates to proteins (e.g., peptides) that are capable of facilitating transport of an active agent through a human or animal gastro-intestinal tissue, and derivatives (e.g., fragments) and analogs thereof, and nucleotide sequences coding for said proteins and derivatives. The proteins of the invention have use in facilitating transport of active agents from the lumenal side of the GIT into the systemic blood system, and / or in targeting active agents to the GIT. Thus, for example, by binding (covalently or noncovalently) a protein of the invention to an orally administered drug, the drug can be targeted to specific receptor sites or transport pathways which are known to operate in the human gastrointestinal tract, thus facilitating its absorption into the systemic system.

The invention provides a sports rehabilitation device for exercising upper and lower limbs, which comprises a bed body, a support frame is fixed on the left side of the bed body, an upper limb training device is arranged on a support top, the upper limb training device comprises two sets of big arm support rods and two sets of small arm support rods, the two sets of the big arm support rods are connected with the support frame by a rotating mechanism, and the two sets of the large arm support rods are also connected with two sets of small support rods through the rotating mechanism; a lower limb training mechanism is arranged on the right side of the bed body, the lower limb training mechanism is fixed on a two-degree-of-freedom sliding mechanism, and the two-degree-of-freedom sliding mechanism is fixed on the bottom of the bed body. The invention provides a sports rehabilitation device for exercising upper and lower limbs, mainly used for performing upper limb lower limb exercise forcerebral infarction or post-operative bedridden patients, through rehabilitation training, the systemic blood circulation can be promoted, the residual muscle strength can be restored, and the joint mobility can be improved.

The present invention provides a percutaneously absorptive preparation for preventing or treating allergic eye disease, which comprises olopatadine or a salt thereof as an active ingredient. In addition, the present invention provides a method for preventing or treating allergic eye disease, which comprises applying a percutaneously absorptive preparation comprising olopatadine or a salt thereof to the skin surface including the skin surface of an eyelid, thereby casing transfer of a therapeutically effective amount of olopatadine or a salt thereof from the preparation to an anterior ocular segment through the skin of the eyelid rather than a systemic blood flow. The present preparation can exert a pharmacological effect over a prolonged period by a single application, as compared to conventional preparations such as eye drops.

The invention discloses a dynamic knee comprehensive-fumigation treatment device. The dynamic knee comprehensive-fumigation treatment device is used in the field of medical apparatuses and instruments and comprises a fumigation barrel, wherein a pot body contained with a medicament and a heat source for heating the pot body are arranged in the fumigation barrel, two sides of the fumigation barrel are oppositely provided with a seat and a foot movement mechanism. The foot movement mechanism is added on the opposite side of the seat of the dynamic knee comprehensive-fumigation treatment device, so that a user can perform continuous foot movement through the foot movement mechanism while being subjected to knee fumigation and then achieve knee joint movement in the mode, the knee and systemic blood vessels further dilate, blood circulation of body surface tissues and copious secretion of sweat glands are promoted, and finally the absorption effect of the skin is improved. The dynamic knee comprehensive-fumigation treatment device is novel in design and conforms to the skin pharmacology.

The invention relates to medicine and veterinary science and can be used for treating diseases associated with changes of the qualitative and / quantitative composition of blood extracellular DNA, namely generalised infection diseases provoked by bacteria, diseases provoked by fungi and protozoa, atherosclerosis, pancreatic diabetes, allergic diseases associated with delayed response hypersensitivity and diseases due to somatic cell gene mutations. The inventive method for treating diseases associated with modifications of the qualitative and / or quantitative composition of blood extracellular DNA, namely generalised infection diseases provoked by bacteria, diseases provoked by fungi and protozoa, atherosclerosis, pancreatic diabetes, allergic diseases associated with delayed response hypersensitivity and diseases due to somatic cell gene mutations consists in injecting an agent destroying blood extracellular DNA. DNAse enzyme injected into a systemic blood circulation in doses which modify the electrophoretic profile of the blood extracellular DNA definable by pulse-electrophoresis can be used in the form of an agent destroying said blood extracellular DNA. Said DNAse enzyme can be injected in doses and at regimes ensuring the level of a blood plasma DNA-hydrolytic activity which is measured in the blood plasma and is higher than 150 Kunz units per litre of plasma during a total time higher than 12 hours a day. The inventive method makes it possible to develop a high-efficient and low-toxic method for treating diseases associated with modifications of qualitative and / or quantitative composition of blood extracellular DNA individually or in combination thereof.

The present invention provides a percutaneously absorptive preparation for preventing or treating allergic eye disease, which comprises epinastine or a salt thereof as an active ingredient. In addition, the present invention provides a method for preventing or treating allergic eye disease, which comprises applying a percutaneously absorptive preparation comprising epinastine or a salt thereof to the skin surface including the skin surface of an eyelid, thereby causing transfer of a therapeutically effective amount of epinastine or a salt thereof from the preparation to an anterior ocular segment through the skin of the eyelid rather than a systemic blood flow. The present preparation can exert a pharmacological effect over a prolonged period by a single application, as compared to conventional preparations such as eye drops.

The invention discloses a hot compress traditional Chinese medicinal composition for promoting rehabilitation of neck-shoulder and lumbocrural pain. The composition consists of the following raw material components in parts by weight: 10-20g of radix saposhnikoviae, 10-30g of rhizoma cibotii, 10-20g of rhizoma seu radix notopterygii, 6-10g of herba ephedra, 8-15g of rhizoma ligustici wallichii, 10-15g of cassia twig, 10-20g of radix clematidis, 6-10g of radix glycyrrhizae preparata, 10-20g of flos carthami, 10-20g of radix angelicae sinensis and 10-20g of eucommia bark. In accordance with diseases, the medicinal components of the weights are crushed and are soaked in a mixed solution of Baijiu which is at 50 degrees in alcoholic strength and rice vinegar in a mode of being packaged in a gauze bag, after 2 days, the medicine bag (the gauze bag) is taken out, liquid in the bag is squeezed out with hands and the medicine bag is steamed in a pot, the medicine bag is taken out after being boiled in the pot for 10min, the medicine bag is cooled and is covered by a preservative film, and then the hot water bag is applied to the medicine bag for 30-60min per time. The traditional Chinese medicine disclosed by the invention, through hot compress, can be used for effectively relaxing muscles and dilating skin capillaries, so that local blood circulation and systemic blood circulation are subsequently improved; and the traditional Chinese medicinal composition has a good effect on various inflammatory responses and painful diseases.

A transdermal drug delivery system for treatment of ophthalmic diseases comprising a structure that a plaster layer containing a remedy for ophthalmic diseases is provided on a support, wherein the system is applied to a skin surface including a front surface of an eyelid to administer the remedy for ophthalmic diseases in the plaster layer to an ophthalmic topical tissue by percutaneous permeation substantially without being administered through a systemic blood flow. Use of the transdermal drug delivery system for treatment of ophthalmic diseases, comprising applying the transdermal drug delivery system to a skin surface including a front surface of an eyelid to transfer the remedy for ophthalmic diseases in the plaster layer to an ophthalmic topical tissue by percutaneous permeation substantially without being administered through a systemic blood flow, and a method for transferring the remedy for ophthalmic diseases to the ophthalmic topical tissue.

This invention relates to proteins (e.g., peptides) that are capable of facilitating transport of an active agent through a human or animal gastrointestinal tissue, and derivatives (e.g., fragments) and analogs thereof, and nucleotide sequences coding for said proteins and derivatives. The proteins of the invention have use in facilitating transport of active agents from the lumenal side of the GIT into the systemic blood system, and / or in targeting active agents to the GIT. Thus, for example, by binding (covalently or noncovalently) a protein of the invention to an orally administered drug, the drug can be targeted to specific receptor sites or transport pathways which are known to operate in the human gastrointestinal tract, thus facilitating its absorption into the systemic system.

A system and accompanying method is provided for assessing a ratio of pulmonary to systemic blood flow in patients with a single-ventricle physiology (SVP). A compound dilution curve is recorded in an arterial vessel downstream of the pulmonary artery. A first component of the compound dilution curve is identified, wherein the first component is attributable to the indicator after passing through the single ventricle heart and directly into the arterial vessel A second component of the compound dilution curve is identified, wherein the second component is attributable to the indicator after passing from the single ventricle heart to the lungs, through the single ventricle heart and then to the arterial vessel downstream of the pulmonary artery. Based on the identified components, the pulmonary flow and systemic flow are assessed as corresponding to the identified first component and second component of the compound dilution curve.

The invention discloses a limb local drug delivery and dialysis device and an application thereof. The limb local drug delivery and dialysis device is characterized in that an arterial blood inlet, an arterial blood outlet and at least one drug delivery inlet are arranged on an arterial chamber, wherein the arterial blood inlet is matched with one end of a main artery, and the arterial blood outlet is matched with the other end of the main artery. A venous blood inlet, a venous blood outlet, a dialysate inlet and a dialysate outlet are arranged on a venous chamber, wherein the venous blood inlet is matched with the limb side of the vein, and the venous blood outlet is matched with the proximal side of the vein. A blood coil of a dialysing tube structure is arranged in the venous chamber, one end of the blood coil is connected with the venous blood inlet, and the other end of the blood coil is connected with the venous blood outlet. The limb local drug delivery and dialysis device filter backflow venous blood molecules with specific sizes while performing arterial drug delivery, provides drugs for limbs on the affected side, and limits the drugs to the blood circulation in the affected limbs; discharges harmful substances generated by the affected limbs and prevents the harmful substances from entering whole-body blood circulation, thereby achieving the purpose of treating localized lesions of the limbs.

The invention discloses a drug spray to accelerate the growth of hair, which comprises the following parts: minuodier, lecithine, vitamin E, natural essential oil and alcohol, wherein all or part of the components can be applied to prepare spray agent with alcohol liposome minuodier, which is covered by liposome to solve the solubility of minuodier and uniformity of drug in the water to strengthen the percutaneous absorption and drug effect after transmitting the drug into derma. The invention avoids side effect to reduce the toxicity for blood circulating system and stimulation for skin, which protects skin effectively.

A method of identifying a peptide which permits or facilitates the transport of an active agent through a human or animal tissue. A predetermined amount of phage from a random phage library or a preselected phage library is administered in vivo or in situ to a site in an animal, such as into the gastro-intestinal tract. At a predetermined time, the phage which is transported across a tissue barrier is harvested at a harvesting site, such as in portal or systemic blood or brain tissue, which is separated from the site of administration by the tissue barrier to select transported phage. This transported phage is amplified in a host. This cycle of events is repeated (using the transported phage produced in the most recent cycle) a predetermined number of times to obtain a selected phage library containing phage which can be transported from the site of administration to the harvesting site. The identity of at least one peptide coded by phage in the selected phage library is determined to identify a peptide which permits or facilitates the transport of an active agent through a human or animal tissue.

The invention discloses a long-necked respirator, which comprises a shell and a flexible sealing ring fixed to the periphery of the lateral face of the shell. The flexible sealing ring can be used for sealing a nose or the outer contour of the nose and a mouth and is provided with fixing straps, the shell is provided with an opening and hermetically connected with a vertical pipe, the upper end of the vertical pipe is forked to respectively form an air outlet pipe and an air inlet pipe, an adjusting valve for plugging the air outlet pipe in air intake and plugging the air inlet pipe in air outtake is arranged at the forked position, a mechanism for partially stopping air is arranged at the upper end of the air outlet pipe, and the air inlet pipe is connected with an air injection mechanism. The long-necked respirator solves the problem that a past respirator can only allow nostrils instead of a mouth to breathe. The long-necked respirator is applicable to underwater emergency treatment for dying people, and can also be used for increasing or activating cell viability, promoting whole body blood circulation, improving respiratory capacity, and achieving the positive effects of helping respiration, starting heart beating and leading a human body to rise again.

The invention discloses an in-vivo closed-loop extraction device for circulating tumor cells (CTC). The device comprises a blood collection unit, wherein the blood collection unit is connected with aprimary separation unit through a first blood transfusion tube; the primary separation unit is connected with a fine separation unit or a storage unit through a second blood transfusion tube; the primary separation unit is further connected with a reverse-transfusion unit through a third blood transfusion tube; the primary separation unit is used for separating blood into components containing thecirculating tumor cells and components containing no circulating tumor cells; the fine separation unit is connected with the reverse-transfusion unit through a fourth blood transfusion tube; the fineseparation unit is further connected with the storage unit through a discharge pipe; the fine separation unit is used for extracting the circulating tumor cells from the components containing the circulating tumor cells; the storage unit is used for storing the components containing the circulating tumor cells and / or the circulating tumor cells; a control unit is separately connected with the blood collection unit, the primary separation unit, the fine separation unit, and the reverse-transfusion unit. The device disclosed by the invention has one beneficial effect that the circulating tumorcells in the whole body can be removed by filtration.

The invention discloses a traditional Chinese medicine oral liquid for treating alopecia. The oral liquid is composed of the following raw material in parts by weight: 5 to 15 parts of fleece-flower root, 10 to 20 parts of radix astragali, 5 to 15 parts of red peony root, 15 to 25 parts of Chinese angelica, 5 to 15 parts of ginseng, 15 to 25 parts of gynostemma pentaphylla, 10 to 25 parts of Chinese gall, and 5 to 15 parts of radix bupleuri. The provided oral liquid is for oral administration, has the functions of nourishing yin and blood, tonifying qi, and regulating blood, is capable of promoting whole-body blood circulation, and effectively treats alopecia caused by blood deficiency.

A method to treat solid tumors and other oncological diseases consists of parenterally injecting an agent which destroy's blood's extracellular DNA into the systemic blood circulation of a cancer patient to slow down malignant. The agent is embodied in the form of a DNAse enzyme and, more particularly, as a bovine pancreatic DNAse. Doses from 50,000-250,000,000 Kunz units / day are injected for 5-360 days. A binding agent or an agent that modifies the chemical composition of the blood extracellular DNA is additionally injected into the blood. This modifying agent is preferably an enzyme-ribonuclease.

The invention provides a metformin anti-aging skin care product, which comprises metformin, other active ingredients, conventional raw materials, auxiliary materials and the like, and can be preparedinto paste, emulsion, cream, a gel, spray, milk, lotion and other forms through dissolving, heating, stirring, cooling and other process methods. According to the invention, the anti-aging drug metformin and other active ingredients in the skin care product can directly act on the surface of skin, or permeate into local or whole-body blood circulation through skin so as to achieve the effect of transdermal drug delivery, and can be used for skin aging resistance, body aging resistance and treatment of various diseases such as type 2 diabetes mellitus, polycystic ovarian syndrome, tumors and other like; with the metformin anti-aging skin care product, the damage to the oral metformin medicine in the gastrointestinal tract, the possible first-pass effect of live and the gastrointestinal inactivation are avoided, the damage to liver and kidney is reduced, toxic and side effects are reduced, and a new method and way are provided for safely and effectively expanding the range of users; andthe anti-skin aging or anti-body aging and the medication method are simple, convenient, easy and acceptable.